The agonizing itching is one of the most difficult symptoms to bear in patients with primary biliary cholangitis (PBC). It can have a far greater impact on everyday life, sleep and mental stability than the laboratory values of the underlying disease. New studies and congress papers from 2025 show that the therapeutic spectrum has expanded significantly in recent years. The focus today is on the targeted modulation of cholestatic mechanisms, in particular through inhibitors of bile acid transport and PPAR agonists, which not only have a favorable effect on the course of the disease but also on the symptom burden.
Autoren
- Tanja Schliebe
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Crohn's disease and depression
Significant psychological stress for CD patients
- Epilepsy
Cannabidiol for refractory epilepsy syndromes
- Stomach cancer and Helicobacter pylori
A question of income?
- Prurigo nodularis and AD
Effective itch relief through inhibition of the IL-31 signaling pathway
- Cutaneous Crohn's disease
Effective alternative to TNF inhibitors
- Palliative care symptom and needs assessment.
What screening tools are helpful?
- Benralizumab in a patient with asthma and EGPA
When the biologic has a counterproductive effect
- Brain atrophy and MS